A Multimodal AI Agent for Ophthalmic Clinical Decision Support (NCT07401459) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Multimodal AI Agent for Ophthalmic Clinical Decision Support
China300 participantsStarted 2026-03-01
Plain-language summary
This study is a multicenter randomized controlled trial evaluating the effectiveness and safety of EyeAgent, a multimodal artificial intelligence (AI) agent designed to assist ophthalmologists in clinical decision-making. Participants will be recruited from ophthalmology clinics and hospitals in Hong Kong and mainland China. The AI agent acts as a digital co-pilot, analyzing patient images and clinical history to provide diagnostic and management recommendations. The trial aims to determine whether the use of the AI agent improves diagnostic accuracy, treatment decision-making performance, report generation, workflow efficiency, and user satisfaction compared to standard clinical practice.
Who can participate
Age range6 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Outpatient participants aged 6 to 75 years.
✓. Participants who undergo ophthalmic examinations for medical purposes during the study period.
✓. Participants who can produce clear ophthalmic images in both eyes.
✓. Agree to participate in this study with written informed consent:
✓. Participants aged 18 years or older provide their own consent.
✓. Participants aged 6-17 years require consent from a parent or legal guardian.
Exclusion criteria
✕. Participants who are reluctant to participate in this study.
✕. Participants presenting with acute or emergency ocular conditions requiring immediate intervention.
✕. Participants with poor quality of ophthalmic images, including blurriness, artifacts, underexposure, or overexposure.